HSPA7 and glioblastoma: In summary, via integrated analysis of our own m6A-seq data and public clinical data, we found highly distinct lncRNA m6A methylation modification patterns between GBM and normal brain tissues and determined that HSPA7 could be used to evaluate the prognosis of GBM patients, as well as the corresponding cellular TME infiltration and activation characteristics of individual patients, and could predict the clinical efficacy of anti-PD-1/-PD-L1 immunotherapy in patients.